Compare HAWK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAWK | COLL |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2026 | 2015 |
| Metric | HAWK | COLL |
|---|---|---|
| Price | $12.33 | $22.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $29.10 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 1.3M | 649.6K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $84.65 | $6.73 |
| Revenue Next Year | $25.27 | $1.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $11.41 | $21.43 |
| 52 Week High | $25.71 | $50.79 |
| Indicator | HAWK | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 49.28 |
| Support Level | N/A | $21.51 |
| Resistance Level | $17.42 | $23.87 |
| Average True Range (ATR) | 0.64 | 0.75 |
| MACD | 0.02 | 0.28 |
| Stochastic Oscillator | 30.89 | 58.86 |
Hawkeye 360 Inc operates in the signals intelligence (SIGINT) and defense technology sector. It provides end-to-end signals intelligence solutions integrated into national security systems for the United States and allied customers. Its offerings include radio frequency data and related insights to support defense operations. The company is involved across the value chain, including satellite design and manufacturing, data collection, and data processing and analysis. It generates revenue prominently from fixed price contract arrangements for RF signal mapping products that are used to analyze and track radio waves.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.